Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 11/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.46 |
| ▸ | KDM5A | P29375 | 2/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ITK | Q08881 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4246412 | 1.00 | HCRTR1 (0.48) | HCRTR1HCRTR2KDM5AGFERGAA | |
| SCHEMBL4245004 | 0.90 | KDM5A (0.47) | HCRTR1HCRTR2KDM5APIK3CDPIK3CA | |
| SCHEMBL3659487 | 0.90 | KDM5A (0.47) | HCRTR1HCRTR2KDM5APIK3CDPIK3CA | |
| SCHEMBL3658083 | 0.86 | HCRTR1 (0.62) | HCRTR1HCRTR2 | |
| SCHEMBL3658078 | 0.86 | HCRTR1 (0.62) | HCRTR1HCRTR2 | |
| SCHEMBL8226209 | 0.86 | HCRTR1 (0.45) | HCRTR1HCRTR2KDM5AEGFRITK | |
| SCHEMBL8227505 | 0.86 | GFER (0.48) | HCRTR1HCRTR2GFERGAAPIK3CD | |
| SCHEMBL4247668 | 0.82 | HCRTR1 (0.47) | HCRTR1HCRTR2KDM5A | |
| SCHEMBL4247661 | 0.82 | HCRTR1 (0.47) | HCRTR1HCRTR2KDM5A | |
| SCHEMBL4249175 | 0.82 | NPC1 (0.47) | HCRTR1HCRTR2KDM5AGAAAPLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897627-B2 | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-03-01 | — | — | US | claimed |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | claimed |
| US-7897627-B2 | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-03-01 | — | — | US | disclosed |
| WO-2009080533-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, MTNR1A | HCRTR1 1/4885HCRTR2 2/4885KDM5A 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.